Geoffrey Lynn

Geoffrey Lynn has an extensive work experience in the field of immunotherapies and medical research. Geoffrey'scurrent role is as SVP of Synthetic Immunotherapies at Vaccitech, a position they started in December 2021. Prior to this, they served as the CEO of Avidea Technologies from October 2016 to December 2021, where they played a crucial role in leading the company. Before entering the industry, Geoffrey gained valuable experience at prestigious institutions such as the National Institutes of Health and the University of Oxford. At the National Institutes of Health, they worked as a Postdoctoral Fellow from January 2015 to July 2016 and as a Graduate Student from September 2010 to December 2014. During their time at the University of Oxford, they were a Graduate Student from October 2010 to December 2014. Additionally, Geoffrey pursued their medical education at the Johns Hopkins School of Medicine, where they were a Medical Student from August 2008 to July 2010.

Geoffrey Lynn's education history is as follows: Geoffrey obtained a Bachelor of Science degree in Chemistry and Biology from Elon University between 2003 and 2007. Following this, they pursued a Doctor of Philosophy (D.Phil.) in Material Sciences and Immunology at the University of Oxford, from 2010 to 2013. Finally, they attended The Johns Hopkins University School of Medicine between 2008 and 2016, where they earned an MD-PhD in Medicine.